Chronic Pain in Rheumatoid Arthritis
NCT05038553
Recruiting
The objective is to identify modifiable clinical factors and neurobiological pathways that lead to the development of chronic pain in patients with early rheumatoid arthritis. Participants will undergo quantitative sensory testing, a type of testing that involves assessing response to well-defined, quantifiable painful stimuli, at 0, 3, and 12 months. A subset of participants will also undergo magnetic resonance imaging at 0 and 12 months to assess neuroimaging markers that have previously been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Colorado, Denver, Colorado +4 locations
Conditions: Arthritis, Rheumatoid, Pain
Register for Updates
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566
Recruiting
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: OPN Healthcare, Inc., Glendale, California +25 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383
Recruiting
This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ PET or other imaging scan after CAR-T infusion. Patients who are planned for salvage chemotherapy less than 14 days after completion of radiation treatment will be excluded. Radiation treatment will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma, Plasma Cell Neoplasm, Malignant Plasma Cell Neoplasm
Register for Updates
Heart Transplantation - Renewal
NCT05521399
Recruiting
Heart transplantation (HTx) is a well-established life-saving procedure but is associated with severe complications. Regular monitoring of heart transplant recipients is thus important for the early detection of these complications. Current standard clinical tests, however, rely on frequent invasive procedures including endomyocardial biopsies (EMB) and catheter angiography (Cath). In addition, these standard tests are limited by sampling error, the diffuse nature of HTx complications, and high... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: Northwestern University- Feinberg School of Medicine, Chicago, Illinois +1 locations
Conditions: Transplant, Heart, Magnetic Resonance Imaging
Register for Updates
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/24/2025
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona +83 locations
Conditions: Ulcerative Colitis
Register for Updates
Metformin for Fibromyalgia Symptoms (INFORM Trial)
NCT05900466
Recruiting
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS pat... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Fibromyalgia Syndrome
Register for Updates
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
NCT05951179
Recruiting
TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Mayo Clinic, Phoenix, Arizona +28 locations
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
NCT06059846
Recruiting
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (≥18 years of age) with cUTI or AP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Medical facility, Miami, Florida +85 locations
Conditions: Urinary Tract Infection, Acute Pyelonephritis
Register for Updates
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
NCT06095089
Recruiting
The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +4 locations
Conditions: Advanced Prostate Cancer
Register for Updates
Obsidio™ Conformable Embolic Registry
NCT06170619
Recruiting
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +19 locations
Conditions: Hypervascular Tumors, Bleeding, Hemorrhage
Register for Updates
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Alabama Neurology Associates- Site Number : 8400019, Birmingham, Alabama +77 locations
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Natural History Study of Kaposi Sarcoma
NCT06375122
Recruiting
Background: Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, and how it affects the immune system and organs. Objective: To learn more about the natural history of KS. Eligibility... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Kaposi Sarcoma, HIV
Register for Updates